A Phase 3 interventional study of Dapagliflozin 10 mg once daily in Atrial Fibrillation (AF), sponsored by Region Stockholm. Recruiting at 7 sites in Sweden. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2025-09-23.
Sponsored by Region Stockholm · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 135 studies in Atrial Fibrillation with a site in Sweden — 24 open to participants now, 36 under way, 5 of them phase 3. Atrial Fibrillation · Sweden.
Among the 135 studies in Atrial Fibrillation with a site in Sweden, this one is the 28th largest by planned enrollment of the 95 interventional ones that give a count, is one of 7 that started in 2025, is one of 29 in phase 3, reaches primary completion later than 19 of the 35 other live ones, and was the 128th registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →24 of the 135 studies in Atrial Fibrillation with a site in Sweden are open now. Recruiting first, the newest first:
Karolinska University Hospital · Sites in Sweden
Ages 78+
Emma Svennberg · Sites in Sweden
Ages 18+
Rahul Raj · Sites in Sweden, Finland
Ages 18+
Johan Sundström · Sites in Sweden
Ages 50–75 · Healthy volunteers
Region Skane · Sites in Sweden
Ages 18+
A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 55 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
135 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 15 · Phase 3 30 · Phase 4 6
First in 1993; this study’s year is marked. 7 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,600 is above the median of 150 across 2,480 interventional studies indexed under Atrial Fibrillation.
Median enrollment 361 across the 95 interventional studies, 480 across the 39 observational. Of the 85 that completed or were terminated, 34 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
59 of 135 have an industry lead sponsor. The 10 most frequent:
Region Stockholm is the lead sponsor of 122 studies on the registry; 70 are open to participants now.
Region Stockholm has 2 studies filed under Atrial Fibrillation — fewer than ten, so there is no comparison to draw.
5 of the studies in Atrial Fibrillation with a site in Sweden that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06696079Rahul RajRestarting Early Versus Later Anticoagulation for Chronic Subdural Hematoma With Atrial Fibrillation | 2026-12 |
| NCT04593498Karolinska InstitutetExcessive Supraventricular Activity and Atrial Fibrillation | 2026-12-31 |
| NCT06656884Boston Scientific CorporationFARAPULSE Workflow Assessment Registry | 2027-02-15 |
| NCT07181590Abbott Medical DevicesBaLloon-based PFA Ablation poST Approval Outcomes for PAF and PersAF | 2027-09 |
| NCT06315192Region SkaneStroke Alarm Efficacy Trial | 2027-10-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 135 studies in Atrial Fibrillation with a site in Sweden, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn if drug dapagliflozin, a sodium-glucose transport-2 inhibitor, works to treat atrial fibrillation in adults. The main question it aims to answer is:
Researchers will compare drug dapagliflozin to standard therapy to see if drug dapagliflozin reduce the recurrence of atrial fibrillation.
Persons with atrial fibrillation who are planned for an electric cardioversion will:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Standard of care
Tablet Dapagliflozin 10 mg once daily
Drug: Dapagliflozin 10 mg once daily
Tablet Dapagliflozin 10 mg orally during from randomization for maximum 56 days.
Atrial fibrillation recurrence
Time to first AF recurrence detected with an ECG- monitoring device within 30 days after planned elective electrical cardioversion.
Time frame: 30 days after elective electrical cardioversion
Proportion of patients in SR at 30 days
Proportion of patients in SR 30 days after cardioversion.
Time frame: 30 days after elective electrical cardioversion
Proportion of patients without any atrial fibrillation recurrence at 30 days
Proportion of patients without any atrial fibrillation recurrence at 30 days
Time frame: 30 days after elective electrical cardioversion
Time to spontaneous return to sinus rhythm before electrical cardioversion
Time to spontaneous return to sinus rhythm measured from randomization to electrical cardioversion (max 26 days)
Time frame: Up to 26 days
Spontaneous return to sinus rhythm before cardioversion.
Number of patients with return to sinus rhythm at time of electrical cardioversion (maximum 26 days from randomization)
Time frame: Up to 26 days
Success of cardioversion
Discharged with sinus rhythm after electric cardioversion
Time frame: Periprocedural
Total number of days with atrial fibrillation
Total number of days with AF recordings during the 30 days following cardioversion.
Time frame: From day of electric cardioversion to 30 days after
Absence of clinical atrial fibrillation recording
Absence of clinical atrial fibrillation recurrence (12-lead ECG-verified) during follow-up after cardioversion or after spontaneous return to SR (before cardioversion).
Time frame: From randomization to 30 days after electric cardioversion
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2025 (actual). Primary completion is estimated for Dec 2027, 30 months after the start.
Of 62 non-industry phase 3 interventional studies under Atrial Fibrillation, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 73. This study's planned 30 months is below that.
Counting every sponsor, half of 83 studies reached it within 42 months; a quarter within 32 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dapagliflozin